Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer

@article{Dowlati2000PhaseIA,
  title={Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer},
  author={Afshin Dowlati and Nathan Levitan and Nahida H. Gordon and Charles L. Hoppel and David M. Gosky and Scot C. Remick and Stephen T. Ingalls and Sossamma J. Berger and Nathan A. Berger},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2000},
  volume={47},
  pages={141-148}
}
Purpose: In vitro and in vivo preclinical models have demonstrated synergistic activity when topoisomerase I and II inhibitors are administered sequentially. Topoisomerase I inhibitors increase topoisomerase II levels and increase cell kill induced by topoisomerase II poisons. We evaluated this hypothesis in a cohort of patients with advanced non-small-cell lung cancer (NSCLC). Methods: A group of 19 patients with advanced NSCLC (70% adenocarcinoma) received topotecan at a dose of 0.85 mg/m2… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-6 of 6 extracted citations

Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2003